Aniracetam

Aniracetam
Clinical data
Trade names	Ampamet, Memodrin, Pergamid
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth
ATC code	N06BX11 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: Unapproved "New Drug" (as defined by 21 U.S. Code § 321(p)(1)). Use in dietary supplements, food, or medicine is unlawful; otherwise uncontrolled.;
Pharmacokinetic data
Elimination half-life	0.5 hours
Identifiers
	IUPAC name 1-[(4-Methoxybenzoyl)]-2-pyrrolidinone;
CAS Number	72432-10-1 ;
PubChem CID	2196;
IUPHAR/BPS	4133;
DrugBank	DB04599 ;
ChemSpider	2111 ;
UNII	5L16LKN964;
KEGG	D01883 ;
ChEBI	CHEBI:47943 ;
ChEMBL	ChEMBL36994 ;
CompTox Dashboard (EPA)	DTXSID5045128 ;
ECHA InfoCard	100.108.230
Chemical and physical data
Formula	C12H13NO3
Molar mass	219.240 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N(C(=O)c1ccc(OC)cc1)CCC2;
	InChI InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3 ; Key:ZXNRTKGTQJPIJK-UHFFFAOYSA-N ;
	(what is this?) (verify)

Aniracetam (brand names Draganon, Sarpul, Ampamet, Memodrin, Referan), also known as N-anisoyl-2-pyrrolidinone, is a racetam which is sold in Europe as a prescription drug. It is not approved by the Food and Drug Administration for use in the United States as a prescription medication or dietary supplement.^[3]^[4] Despite the FDA's lack of approval, the drug is readily available over-the-counter in misbranded dietary supplements.^[3]

^ Roncari G (June 1993). "Human Pharmacokinetics of Aniracetam". Drug Investigation. 5 (S1): 68–72. doi:10.1007/BF03258428. S2CID 96775295.
^ Cite error: The named reference lee was invoked but never defined (see the help page).
^ ^a ^b Malykh AG, Sadaie MR (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767. S2CID 12176745.
^ Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I (June 2021). "Five Unapproved Drugs Found in Cognitive Enhancement Supplements". Neurology. Clinical Practice. 11 (3): e303 – e307. doi:10.1212/CPJ.0000000000000960. PMC 8382366. PMID 34484905.

[1] Roncari G (June 1993). "Human Pharmacokinetics of Aniracetam". Drug Investigation. 5 (S1): 68–72. doi:10.1007/BF03258428. S2CID 96775295.

[lee-2] Cite error: The named reference lee was invoked but never defined (see the help page).

[Neuro-3] Malykh AG, Sadaie MR (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767. S2CID 12176745.

[4] Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I (June 2021). "Five Unapproved Drugs Found in Cognitive Enhancement Supplements". Neurology. Clinical Practice. 11 (3): e303 – e307. doi:10.1212/CPJ.0000000000000960. PMC 8382366. PMID 34484905.

[1]

[2]

[3]

[4]